Back to the WireInvesting.com
DevelopingInvesting.com ·
Revolution Medicines reports updated pancreatic cancer trial data
Revolution Medicines has reported updated data from a pancreatic cancer trial, according to a headline-only report. The details of the results are not available in this item.
Who is reporting it
- GlobeNewswirefirst at Nov 19, 2026, 6:05 PM ESTRead at GlobeNewswire (opens in a new tab)
- Investing.comfirst at Nov 19, 2026, 6:08 PM ESTRead at Investing.com (opens in a new tab)
Story so far
Reported by 2 sources
Revolution Medicines presented updated Phase 1/2 data for RASONQUE (daraxonrasib) combined with gemcitabine and nab-paclitaxel as a possible first-line treatment for metastatic pancreatic cancer at the ENA Symposium in Barcelona.
- Nov 19, 2026, 6:05 PM EST · GlobeNewswireConfirmedRevolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026
- Nov 19, 2026, 6:08 PM EST · Investing.com · this storyDevelopingRevolution Medicines reports updated pancreatic cancer trial data
Comments
Log in or create a free account to comment.
No comments yet.
The headline links to the original source; the summary is written by The Market Standard. Nothing here is financial advice.